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Abstract
Background: Dysregulation of innate immune response by Toll-Like Receptors (TLRs) is a key feature in Ulcerative
Colitis (UC). Most studies have focused on TLR2, TLR3, and TLR4 participation in UC. However, few studies have
explored other TLRs. Therefore, the aim of this study was to evaluate the mRNA profiles of TLR1 to 9 in colonic
mucosa of UC patients, according to disease activity.
Methods: Colonic biopsies were taken from colon during colonoscopy in 51 patients with Ulcerative Colitis and 36
healthy controls. mRNA levels of TLR1 to 9, Tollip, inflammatory cytokines IL6 and TNF were assessed by RT-qPCR
with hydrolysis probes. Characterization of TLR9 protein expression was performed by Immunohistochemistry.
Results: Toll-like receptors TLR8, TLR9, and IL6 mRNA levels were significantly higher in the colonic mucosa from
UC patients (both quiescent and active) as compared to healthy individuals (p < 0.04). In the UC patients group
the TLR2, TLR4, TLR8 and TLR9 mRNA levels were found to be significantly lower in patients with quiescent disease,
as compared to those with active disease (p < 0.05), whereas TLR5 showed a trend (p = 0.06). IL6 and TNF mRNA
levels were significantly higher in the presence of active disease and help to discriminate between quiescent and
active disease (p < 0.05). Also, IL6 and TNF mRNA positively correlate with TLRs mRNA with the exception for TLR3,
with stronger correlations for TLR5, TLR8, and TLR9 (p < 0.0001). TLR9 protein expression was mainly in the lamina
propria infiltrate.
Conclusions: This study demonstrates that TLR2, TLR4, TLR8, and TLR9 expression increases in active UC patients,
and that the mRNA levels positively correlate with the severity of intestinal inflammation as well as with
inflammatory cytokines.
Background
Ulcerative colitis (UC) is a subtype of Inflammatory
Bowel Disease (IBD) characterized by relapsing and
chronic inflammation of colonic mucosa [1]. In Mexico,
the frequency of new cases of UC has tripled during the
last 20 years [2]. The etiology of UC is currently
unknown, however inflammation is hypothesized to
result from inappropriate activation of mucosal immu-
nity by environmental factors such as gut microbiota
[3]. Innate immunity mechanisms involved in recogni-
tion of microorganisms are thought implicated in many
inflammatory conditions [4]. The Toll-like receptors
(TLRs) have been clearly implicated in maintaining gut
homeostasis and in the development of IBD [5] although
the participation of the whole TLR family in the colonic
mucosa from UC patients has not been fully explored.
TLRs are key regulators of the innate immune system
in the gut through the induction of pro-inflammatory
and immunomodulatory responses in many cell types
including immune and epithelial cells [6]. TLR1 to 9
have been reported detectable in human intestine at
least in the mRNA levels both in healthy and disease
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protein have been reported to be up-regulated in IBD
and in other intestinal inflammatory conditions [7-11].
In a recent study, published by Steenholdt, the TLR8
expression was found to be up-regulated in isolated cells
from the colonic epithelial in patients with Crohn’sd i s -
ease and UC [12]. Also, very recently TLR5 expression
was reported down-regulated in patients with UC [13].
To our knowledge, no previous studies have explored
the mRNA expression of TLR1 to 9 mRNA in the colo-
nic biopsies from UC patients. Previous studies have
focused mainly on the study of TLR2, TLR3 and, TLR4,
however, other TLRs expression has not been exten-
sively evaluated in UC patients. In gene expression stu-
dies, determination of mRNA levels by quantitative real
time PCR (RT-qPCR) is a very robust method that has
been used successfully in the IBD field [14,15]. Quantifi-
cation of cytokines and chemokines mRNAs by this
method has shown to be as an interesting tool to evalu-
a t eI B Dd i s e a s ea c t i v i t y[ 1 4 , 1 6 , 1 7 ] .R T - q P C Ra l s oh a s
been traditionally used as gold standard to validate
microarray results, due to its good variance coefficient
in low level transcripts such as cytokines [18,19].
The aim of this study was to characterize the tran-
script patterns of TLR1 to 9 in colonic biopsies from
UC patients according to activity.
Methods
Population and tissue samples
A total of 87 individuals were studied and divided in 3
groups: 1) Active UC (n = 30); 2) Quiescent UC (n =
21) and Healthy control group (n = 36) table 1. All UC
patients had a confirmed diagnosis of UC by histo-
pathology and were recruited from the Inflammatory
Bowel Disease Clinic at the National Institute of Medical
Sciences between November 2007 and May 2009.
Healthy controls consisted of those individuals who
consent to colonoscopy for other reasons such as color-
ectal cancer screening, weight loss and anaemia. The
inclusion criterion was histological normal findings on
intestinal biopsy. Details of demographic and clinical
characteristics of UC were obtained by a questionnaire,
review of records and personal interview. Disease exten-
sion was defined by colonoscopy. The disease activity
was determined by Mayo score and Riley criteria for
endoscopic and histological activity respectively [20].
Ethical considerations
This work was performed to the principles expressed in
the Declaration of Helsinsky. This study was approved
by the ethical committee in our hospital and a written
informed consent was obtained from all patients and
controls.
Sample processing RNA extraction and cDNA synthesis
A l l8 7i n t e s t i n a lm u c o s a lb i opsies taken from colono-
scopy were immediately placed in RNA later (Ambion,
A u s t i n ,T X ,U S A )a n ds t o r e da t- 7 0 ° Cu n t i lp r o c e s s i n g .
Then RNA isolation from all biopsies was performed
with High Pure RNA Tissue Kit (ROCHE, Sciences,
Maryland, USA) according to the manufacturer’s instruc-
tions. The evaluation of RNA integrity, concentration,
and purity was done by ribosomal visualizing RNA 18S
and 28S integrity on agarose 1.5% gels, and by spectro-
photometer on NanoDrop 2000 respectively (Thermo
Fisher Scientific Lafayette, CO, USA). Duplicate cDNA
synthesis was performed from 250 ng of total RNA using
random hexamers and the Transcriptor first strand
cDNA synthesis kit (ROCHE, Sciences, Maryland, USA).
Real time RT-qPCR
RT-qPCR analysis was performed using Roche LightCycler
2.0 (ROCHE, Reuskreutz, Swisserland) with LNA hydroly-
sis probes from the Universal Probe Library Roche (UPL),
and intron spanning designed primers (table 2) from Invi-
trogen (Carlsbad California, USA). One μlo fc D N Aw a s
amplified with 200nM of primers, 100 nM of UPL probe,
with the LighCycler TaqMan
® Master (ROCHE, Sciences,
Maryland, USA) followed by 45 cycles of 95° 10 sec. 60° 30
sec., and 72° 1 sec. Reference genes RPLP0, ACTB,a n d
GAPDH transcripts were used for relative quantification.
For qPCR assays quality control, determination of linearity
and reproducibility was evaluated (VC < 10%). The mRNA
relative quantification of target genes was conducted using
the LightCycler software 4.1, according to the 2-ΔΔCt
method. The calibrator sample employed was the same
patient sample performed in all runs.
Immunohistochemistry
Samples from six UC patients with and without
inflammatory activity were included for TLR9
Table 1 Clinical and demographic characteristics of
Ulcerative Colitis Patients
Patients Number Gender (M/F) 24/27
Age (years range) 41 (19-75)
Disease Duration (1-3/> 3 years) 10/40
Disease Activity (active/quiescent) 21/30
Disease Extension: distal colitis/Pancolitis 21/30
Endoscopic Activity (inactive/mild/moderate/severe) 20/8/12/11
Histological Activity (inactive/mild/moderate/severe) 13/16/12/10
Current therapy: 5-aminosalicylate/Corticosteroids 23/18
Extra-intestinal Manifestations (without/arthritis/other) 31/18/8
Smoking habits (Current smoker/non-smoker/ex-smoker) 32/11/8
Healthy Control Group
Number of Patients Sex (M/F) 14/22
Age (years range) 46 (18-64)
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Page 2 of 9Immunohistochemistry. Peroxidase staining of paraffin-
embedded tissue slides was performed using standard
protocols. Briefly, after deparaffinizing and demasking of
antigens, endogenous peroxidases were blocked with
H2O2. Slides were blocked with 10% normal serum and
were incubated with avidin and biotin. Following incu-
bation with the primary antibody overnight at 4°C, slides
were incubated with the secondary, biotin-conjugated
antibody. Next, they were incubated with HRP-streptavi-
din, followed by incubation with the peroxidase sub-
strate 3’-diaminobenzidine (DAB). In the negative
controls, cells were stained omitting the primary
antibody.
Statistical Analysis
Statistical analysis was performed using SPSS Ver. 15
statistical package program. Statistical significance was
considered when p value was < 0.05. Descriptive statis-
tics were used as means and standard deviations and
medians and interquartilar range. Kolmogorov-Smirnoff
normality test determined RNA data distribution. Krus-
kal-Wallis and Mann Whitney U non parametric tests
were used to test differences among groups, and Spear-
man correlation to asses the relationship between TLR1
to 9, TNF and IL6 RNA levels and the endoscopic and
histological parameters.
Results
TLR1 to 9 mRNA profiles in UC compared with Controls
The TLR1 to 9,T O L L I P ,a n dTNF and IL6 mRNAs
were detectable and quantifiable by RT-qPCR in intest-
inal biopsies from UC patients with quiescent and active
disease as well as in healthy controls (table 3). TLR4,
TLR8, and TLR9 mRNA levels were higher in the overall
UC patients compared to healthy controls (p < 0.04)
(table 3). We found a significantly increased expression
of TLR2, TLR4, TLR8,a n dTLR9 mRNA expression in
the colonic mucosa biopsies from patients with active
Table 2 Primers Designs for qPCR
Gene GENEBANK PRIMERS (5’-3’) Amplicon Size (bp) PROBE UPL
TLR1 NM_003263.3 CCTAGCAGTTATCACAAGCTCAAA 70 #79
TCTTTTCCTTGGGCCATTC
TLR2 NM_003264.3 CGTTCTCTCAGGTGACTGCTC 66 #14
TCTCCTTTGGATCCTGCTTG
TLR3 NM_003265.2 AGTTGTCATCGAATCAAATTAAAGAG 61 #80
AATCTTCCAATTGCGTGAAAA
TLR4 NM_138554.2 CTGCGTGAGACCAGAAAGC 75 #33
TTCAGCTCCATGCATTGATAA
TLR5 NM_003268.4 GACACAATCTCGGCTGACTG 105 #16
TCAGGAACATGAACATCAATCTG
TLR6 NM_006068.2 TGAAACAGTCTCTTTTGSGTAAATGC 72 #55
CAGAATCCATTTGGGAAAGC
TLR7 NM_016562.3 CCAGTGTCTAAAGAACCTGGAAA 63 #5
TCAGGGACAGTGGTCAGTTG
TLR8 NM_138636.2 AGCACTTCCCTCAGGAAGATT 62 #27
NM_016610.2 AGCACCTTCAGATGAGGCATA
TLR9 NM_017442.2 CCAGACCCTCTGGAGAAGC 133 #81
GTAGGAAGGCAGGCAAGGT
TOLLIP NM_019009.2 TCCCCGCTGGAATAAGGT 95 #86
CGTCCATGGAGAAGGCTCT
TNFA NM_000594.2 CAGCCTCTTCTCCTTCCTGA 123 #29
GCCAGAGGGCTGATTAGAGA
IL6 NM_000600 GCCCAGCTATGAACTCCTTCT 86 #45
GAAGGCAGCAGGCAACAC
*RPLP0 NM_001002.3 ACAGGGCGACCTGGAAGT 117 #32
NM_053275.3 GGATCTGCTGCATCTGCTT
*GADPH NM_002046.3 AGCCACATCGCTCAGACAC 66 #60
GCCCAATACGACCAAATCC
ACTB ENST00000331789.2 CAACCGCGAGAAGATGAC 121 560 nm
GTCCATCACGATGCCAGT
Note. TLR8, and RPLP0 assays were designed to detect both transcript isoforms, UPL (Universal Probe Library).
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Page 3 of 9UC compared with both quiescent UC and healthy con-
trols (p ≤ 0.05) (table 3). Comparisons between the
quiescent group and the control group, only showed a
significant up-regulation for TLR4 mRNA levels (p =
0.04) (table 3), while the TLR2, TLR8 and TLR9 mRNA
levels were similar in the healthy control and quiescent
UC group (table 3). Interestingly, the TLR5 mRNA
levels tend to be lower in the quiescent UC group as
compared to active UC (p = 0.06) (table 3). The other
TLRs (TLR1, TLR3, TLR6 and TLR7)a n dTOLLIP
mRNA levels showed change in gene expression when
comparing groups (p > 0.1) (table 3).
Correlation of TLR5, TLR8, TLR9, and IL6 mRNA levels with
endoscopic and histological activity
To further evaluate the relation of less studied TLRs
mRNA levels in IBD and gut inflammation in UC
patients. We evaluated the correlation between TLR5,
TLR8, TLR9 and IL6 mRNA expression levels and endo-
scopic (Figure 1) as well as histological activity (Figure
2) both activity scales were evaluated in a blinded fash-
ion. Comparisons among groups are shown in the fig-
ures 1 and 2, TLR5, TLR5 TLR5 and IL6 mRNA levels
were higher in the inflammatory active groups (p values
are shown in the figures). Positive correlations were
found for the mRNA levels of TLR5 (r = 0.387; p =
0.005), TLR8 ( r=0 . 4 6 5 ;p=0 . 0 0 1 ) ,TLR9 (r = 0.288; p
= 0.04), and IL6 (r = 0.439; p = 0.001) with endoscopic
activity as shown in Figure 1. On the other hand, the
mRNA levels of TLR5, TLR8, TLR9,a n dIL6 correlation
with histological activity, such as TLR5 (r = 0.341; p =
0.015), TLR8 (r = 0.577; p < 0.001), TLR9 (r = 0.428; p
= 0.002), and IL6 (r = 0.633; p < 0.001) as shown in Fig-
ure 2. The TLRs mRNA positive correlations with endo-
scopic and histological activity tend to be significantly
higher analysing the subset of patients who did not
received any steroid treatment at the moment of the
study (overall r > 0.6; p < 0.01).
TLRs mRNA levels correlate with IL6, and TNF mRNA
levels in the colonic mucosa from UC patients
In this study, we also found that in particular IL6
mRNA levels strongly correlate with disease activity.
The IL6 mRNA levels showed an important capacity to
differentiate between quiescent and active disease
(Receiver Operator Curve, AUC = 0.876; p < 0.0001)
compared to TNF (Receiver Operator Curve, AUC =
0.700; p < 0.0001). Therefore, in we explore the corre-
lation of IL6 and TNF mRNA levels as inflammatory
markers with the TLRs mRNA levels. We found that
IL6 and TNF mRNA levels showed a positive correla-
tion with TLRs (TLR1, TLR2, TLR4, TLR5, TLR6,
TLR8 and TLR9) (table 4). The most relevant associa-
tion was found between IL6 and TLR8 mRNA levels
showing also an r2 = 0.4626 p < 0.01 by linear regres-
sion analysis.
Mucosa-Infiltrating Immune Cells Are a Major Source of
Intestinal TLR9 Expression
In order to further characterize the cells responsible for
TLR9 expression, we determine in situ TLR9 protein
expression from intestinal biopsies of UC patients, tis-
sues were immunostained and compared with non-
inflamed tissue (Figure 3e-f). The percentage of TLR9
immunoreactive cells was higher in UC patients com-
pared to controls. TLR9+ cells were localized mainly in
mucosa (Figure 3) lamina propria and perivascular
inflammatory infiltrates (Figure 3d and 3e) but not in
goblet cells, crypt lumen or crypt branching, neither
submucosa.
Table 3 Transcript levels of TLRs and pro-inflammatory cytokines in colonic mucosa from UC patients and Controls
GENE
mRNA
Control N
=3 6
UC Patients N
=5 1
UC Quiescent N
=2 1
UC Active N
=3 1
Control vs
UC
Control vs UC
Quiescent
Control vs UC
Active
UC Quiescent vs
Active
Transcript Levels P value
TLR1 0.75±0.50 1.12±1.63 1.33±2.51 0.98±0.53 0.26 0.64 0.13 0.11
TLR2 0.63±0.25 1.63±2.5 0.72±0.4 2.55±3.30 0.14 0.9 0.001 0.002
TLR3 0.54±0.25 0.75±0.5 0.87±0.60 0.63±0.39 0.6 0.18 0.7 0.27
TLR4 0.64±0.23 1.3±0.94 1.01±0.62 1.55±1.12 0.002 0.015 0.0001 0.04
TLR5 0.94±0.58 0.86±0.5 0.71±0.46 0.96±0.52 0.75 0.14 0.55 0.06*
TLR6 0.91±0.61 0.8±0.67 0.59±0.36 0.94±0.79 0.52 0.11 0.56 0.19
TLR7 0.71±0.45 0.62±0.79 0.77±1.21 0.52±0.27 0.86 0.14 0.13 0.82
TLR8 1.13±0.73 1.96±2.19 0.88±0.59 2.67±2.56 0.04 0.22 0.001 0.0005
TLR9 0.75±0.57 1.12±1.1 0.66±0.37 1.60±1.26 0.037 0.95 0.004 0.006
TOLLIP 0.79±0.21 0.84±0.28 0.85±0.32 0.83±0.26 0.41 0.69 0.82 0.86
TNF 0.96±1.28 0.84±0.79 0.4±0.37 1.24±0.86 0.96 0.01 0.023 < 0.001
IL6 1.8±3.5 8±19.5 1.6±3.2 11±23 0.039 0.8 < 0.001 < 0.001
Transcript levels are shown as means and standard deviations. P with significance are underlined and * for trend.
Sánchez-Muñoz et al. BMC Gastroenterology 2011, 11:138
http://www.biomedcentral.com/1471-230X/11/138
Page 4 of 9Discussion
In the present study, we found that gene expression of
TLR2, TLR4, TLR8 and TLR9 was substantially up-
regulated active UC patients. In particular, less studied
TLR5, TLR8 and TLR9 gene expression positively cor-
related with the presence of UC and the severity of
endoscopic and histological inflammation. The IL6 and
TNF gene expression showed the same trend as TLRs.
The other TLRs (TLR1, TLR3, TLR6, TLR7),a n dTOL-
LIP mRNA levels were not found to be significantly
altered in the presence of active UC. Our results cor-
roborate previously reported results for TLR2 and
TLR4 gene expression in IBD [7,8,11,21] and in general
for intestinal inflammation such as Celiac Disease and
IBS [9,22].
We found also that TLR5 mRNA tends to be up-regu-
lated in active UC compared to UC quiescent disease (p
= 0.06), but we also found that TLR5 also tends to be
down-regulated in UC quiescent disease compared to
healthy mucosa colonic controls (p = 0.14). In a pre-
vious study, Cario and Podolsky reported no changes of
TLR5 expression in the colonic mucosa from IBD
patients [7]. Stanislawowski and colleagues found a
negative correlation between TLR5 and both macrosco-
pically and microscopically inflammation [7,13]. We
suspect that this different finding can be possibly due to
a regulation of the TLR5 transcript levels by steroids
therapy, because we do not found significant Spearman
correlations of TLR5 mRNA and disease activity indexes
(p > 0.1) compared to patients treated only with 5-ASA
Figure 1 Toll-like receptors TLR5, TLR8,a n dTLR9 mRNA levels in Ulcerative Colitis correlate with Endoscopic Activity.R T - q P C Rw a s
performed to assess mRNA levels in colonic mucosa biopsies from UC patients according to Mayo subscore endoscopic activity, bars show
means with standard error of the mean of TLRs and IL6 transcript levels with RPLP0 as housekeeping gene determined by 2
-ΔΔCt, differences
among groups were assessed by Mann-Whitney U test, and p values are presented in the figure.
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Page 5 of 9(p < 0.002). In addition, our results also show that
TLR5 up-regulation is related to inflammation as seen
in colectomized UC patients who developed pouchitis
[23]. Also, Brint et al. recently found that TLR5 mRNA
was up-regulated in colonic biopsies from active Irrita-
ble Bowel Syndrome patients [22].
The TLR8 gene expression in colonic mucosa deter-
mined by us confirmed the results published by Steen-
h o l d te ta l .w h os h o w e dt h a tt h eTLR8 expression was
highly up-regulated in colonic epithelial cells from active
UC patients [12]. The functional consequence for TLR8
up-regulation in the gut is unknown, although except
for TLR2 all other TLRs in epithelial cells induce pro-
inflammatory signals [5]. TLR8 induction of IL8 by
ligands in human isolated epithelial cells stimulated has
been reported [12]. We suspect that TLR8 up-regulation
Figure 2 Toll-like receptors TLR5, TLR8,a n dTLR9 mRNA levels in Ulcerative Colitis correlate with Histological Activity.R T - q P C Rw a s
performed to assess mRNA levels in colonic mucosa biopsies from UC patients according to Riley Histological Activity, bars show means with
standard error of the mean of TLRs and IL6 transcript levels with RPLP0 as housekeeping gene determined by 2
-ΔΔCt, differences among groups
were assessed by Mann-Whitney U test, and p values are presented in the figure.
Table 4 Toll-like receptors and Tollip mRNA correlations
with IL6 and TNF mRNAs in Rectum mucosa from UC
patients
Gene Transcript IL6 TNF
Rho P Rho P
TLR1 0.589 < 0.001 0.572 < 0.001
TLR2 0.626 < 0.001 0.704 < 0.001
TLR3 -0.28 0.089 -0.069 0.679
TLR4 0.367 0.023 0.546 < 0.001
TLR5 0.565 < 0.001 0.615 < 0.001
TLR6 0.387 0.007 0.561 0.001
TLR7 0.34 0.05 0.242 0.168
TLR8 0.681 < 0.001 0.623 < 0.001
TLR9 0.583 < 0.001 0.643 < 0.001
TOLLIP -0.264 0.11 -0.065 0.698
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Page 6 of 9Figure 3 TLR9 increased detection in positive infiltrating immune cells in active UC. Representative immunoperoxidase analysis of TLR9
expression of inflamed colonic tissue from six patients (panel A-D) uninflamed colonic tissue (panel E-F) and taken from a representative patient
with UC. In the negative controls (neg. ctrl), the secondary antibody was omitted. Original magnification was 20 × (panels A, C, D).
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Page 7 of 9in colonic epithelial cells may induce an exacerbated
inflammatory response against not well studied gut
microbiota virus or bacterial RNA resulting from micro-
biota dysbiosis.
Although for the case TLR9, expression was initially
reported down-regulated in inflamed colonic mucosa
from IBD patients [24]. On the other hand, we found
that TLR9 gene expression was up-regulated in the pre-
sence of active UC and compared to healthy mucosa
controls [25]. In the present study, we also found that
TLR9 mRNA levels positively correlate with disease
activity scores in a blinded fashion. Interestingly in a
study conducted in the dog IBD form of disease colonic
TLR2, TLR4,a n dTLR9 mRNA levels are up-regulated
[26]. Also, for the TLR9 case we decide to corroborate
protein expression by immunohistochemistry because of
the differing results in determining the protein expres-
sion in colonic samples. We found that the most evident
source of TLR9 up-regulation levels during inflamma-
tion were the mucosal infiltrating cells. In agreement
with our results, Pedersen et al. reported very little
TLR9 protein expression in isolated colonic epithelial
cells assed by western blot [24]. To our knowledge,
almost all other studies have analysed TLR9 expression
in cell lines [27-29]. Our findings are relevant because
previous a previous study reported by Hall et al. showed
that Dendritic Cells signalling via TLR9 in response to
commensal bacterial DNA inhibits Treg differentiation
in the Gut [30]. Also, in vitro TLR9 expression has been
reported induced by pathogenic bacterial DNA, in
agreement to possible deleterious role of TLR9 signalling
in the gut [27]. Finally, TLR9 frequent promoter poly-
morphisms associated with IBD might up-regulate TLR9
gene expression [31,32]. We believe that gut inflamma-
tion with leukocyte infiltration and dysbiosis both play a
role in the up-regulation of TLR9 expression in the
colonic mucosa of UC patients.
In order to evaluate the relation between inflammation
and TLR gene expression, we also determine the corre-
lations between TLR1 to 9 mRNA expression and
mRNA levels of pro-inflammatory cytokines such as
TNF and IL6 (Table 4). It is well known that TNF and
IL6 mRNA profiles positively correlate with inflamma-
tory activity and especially IL6 can be used as activity
marker in UC [16,17]. We also found that TLR8 mRNA
levels are useful and efficient means to discriminate
between active and quiescent UC.
Finally, the main limitations of our study are the lack
of assessment of putative regulatory TLRs promoter
polymorphisms, and the evaluation of colonic isolated
epithelial and lamina propria isolated colonic cells will
corroborate functional consequence of Toll-like recep-
tors cross-talk.
Conclusions
The TLR5, TLR8 and TLR9 gene expression were up-
regulated in patients with active UC and had a positive
correlation with endoscopic and histological activity.
The functional consequence of TLRs over-expression in
the mucosa from UC patients needs to be further
clarified.
Acknowledgements
FSM had Conacyt (12905) scholarship during the development of this
research; this research was funded by the Department of Gastroenterology
at the Institute of Medical Sciences and Nutrition Salvador Zubiran
(INCMNSZ).
Author details
1Doctorado en Ciencias Biológicas y de la Salud, Universidad Autónoma
Metropolitana, D.F., México.
2Department of Gastroenterology, Instituto
Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, D. F., México.
3Departament of Endoscopy, Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubiran, D. F., México.
4Fundación Clínica Médica Sur,
Puente de Piedra 150, D. F., México.
5Department of Health Care.
Universidad Autónoma Metropolitana, D.F., México.
6Department of
Immunology. Instituto Nacional de Cardiología “Ignacio Chávez”, D. F.,
México.
Authors’ contributions
All authors read and approved the final manuscript; FSM participate during
the sample processing, performed RT-qPCR analysis for TLR mRNA levels and
prepared the manuscript. GFC participate during the sample collecting,
processing, RT-qPCR analysis for cytokine transcript level quantification and
TLR9 Immunohistochemistry. MAVR participate during the sample
recollecting, processing, and non-colitis control characterization. EMP
participated during the sample recollecting and data analysis. EJM
participate during the sample recollecting and data analysis. RBZ assessed
clinical and endoscopic analysis and diagnostics and sampling procedures.
MU did critical reviewing and guiding and data analysis. RB participated in
critical reviewing and data discussion and analysis. ADL critical reviewing
and bibliographic analysis, JKYF designed and provided the research idea,
directed, reassessed both clinical and histological diagnostic, and coordinate
the manuscript editing.
Competing interests
The authors declare that they have no competing interests.
Received: 14 October 2010 Accepted: 20 December 2011
Published: 20 December 2011
References
1. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002,
347(6):417-429.
2. Yamamoto-Furusho JK: Clinical epidemiology of ulcerative colitis in
Mexico: a single hospital-based study in a 20-year period (1987-2006). J
Clin Gastroenterol 2009, 43(3):221-224.
3. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory
bowel disease. Nature 2007, 448(7152):427-434.
4. Drexler SK, Foxwell BM: The role of toll-like receptors in chronic
inflammation. Int J Biochem Cell Biol 2010, 42(4):506-518.
5. Abreu MT: Toll-like receptor signalling in the intestinal epithelium: how
bacterial recognition shapes intestinal function. Nat Rev Immunol 2010,
10(2):131-144.
6. Akira S, Takeda K: Toll-like receptor signalling. Nat Rev Immunol 2004,
4(7):499-511.
7. Cario E, Podolsky DK: Differential alteration in intestinal epithelial cell
expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel
disease. Infect Immun 2000, 68(12):7010-7017.
8. Hausmann M, Kiessling S, Mestermann S, Webb G, Spottl T, Andus T,
Scholmerich J, Herfarth H, Ray K, Falk W, et al: Toll-like receptors 2 and 4
Sánchez-Muñoz et al. BMC Gastroenterology 2011, 11:138
http://www.biomedcentral.com/1471-230X/11/138
Page 8 of 9are up-regulated during intestinal inflammation. Gastroenterology 2002,
122(7):1987-2000.
9. Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Bokodi G, Vasarhelyi B,
Korponay-Szabo IR, Tulassay T, Arato A: Increased mucosal expression of
Toll-like receptor (TLR)2 and TLR4 in coeliac disease. J Pediatr
Gastroenterol Nutr 2007, 45(2):187-193.
10. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H:
Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy
samples of patients with inflammatory bowel diseases: upregulated
expression of TLR2 in terminal ileum of patients with ulcerative colitis. J
Histochem Cytochem 2008, 56(3):267-274.
11. Szebeni B, Veres G, Dezsofi A, Rusai K, Vannay A, Mraz M, Majorova E,
Arato A: Increased expression of Toll-like receptor (TLR) 2 and TLR4 in
the colonic mucosa of children with inflammatory bowel disease. Clin
Exp Immunol 2008, 151(1):34-41.
12. Steenholdt C, Andresen L, Pedersen G, Hansen A, Brynskov J: Expression
and function of toll-like receptor 8 and Tollip in colonic epithelial cells
from patients with inflammatory bowel disease. Scand J Gastroenterol
2009, 44(2):195-204.
13. Stanislawowski M, Wierzbicki PM, Golab A, Adrych K, Kartanowicz D,
Wypych J, Godlewski J, Smoczynski M, Kmiec Z: Decreased Toll-like
receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients.
J Physiol Pharmacol 2009, 60(Suppl 4):71-75.
14. Zahn A, Giese T, Karner M, Braun A, Hinz U, Stremmel W, Ehehalt R:
Transcript levels of different cytokines and chemokines correlate with
clinical and endoscopic activity in ulcerative colitis. BMC Gastroenterol
2009, 9:13.
15. Eriksson A, Flach CF, Lindgren A, Kvifors E, Lange S: Five mucosal
transcripts of interest in ulcerative colitis identified by quantitative real-
time PCR: a prospective study. BMC Gastroenterol 2008, 8:34.
16. Matsuda R, Koide T, Tokoro C, Yamamoto T, Godai T, Morohashi T, Fujita Y,
Takahashi D, Kawana I, Suzuki S, et al: Quantitive cytokine mRNA
expression profiles in the colonic mucosa of patients with steroid naive
ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis
2009, 15(3):328-334.
17. Fonseca-Camarillo G, Villeda-Ramirez M, Sanchez-Munoz F, Barreto-Zuniga R,
Dominguez-Lopez A, Uribe-Esquivel M, Yamamoto-Furusho J: [IL-6 and
TNF-a gene expression in the rectal mucosal of patients with chronic
idiopathic ulcerative colitis and controls.]. Rev Gastroenterol Mex 2009,
74(4):334-340.
18. Noble CL, Abbas AR, Cornelius J, Lees CW, Ho GT, Toy K, Modrusan Z, Pal N,
Zhong F, Chalasani S, et al: Regional variation in gene expression in the
healthy colon is dysregulated in ulcerative colitis. Gut 2008,
57(10):1398-1405.
19. Bustin SA, Dorudi S: The value of microarray techniques for quantitative
gene profiling in molecular diagnostics. Trends Mol Med 2002,
8(6):269-272.
20. Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA: Comparison
of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine
in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988,
29(5):669-674.
21. Toiyama Y, Araki T, Yoshiyama S, Hiro J, Miki C, Kusunoki M: The expression
patterns of Toll-like receptors in the ileal pouch mucosa of
postoperative ulcerative colitis patients. Surg Today 2006, 36(3):287-290.
22. Brint EK, Macsharry J, Fanning A, Shanahan F, Quigley EM: Differential
expression of toll-like receptors in patients with irritable bowel
syndrome. Am J Gastroenterol 2011, 106(2):329-336.
23. Heuschen G, Leowardi C, Hinz U, Autschbach F, Stallmach A, Herfarth C,
Heuschen UA: Differential expression of toll-like receptor 3 and 5 in ileal
pouch mucosa of ulcerative colitis patients. Int J Colorectal Dis 2007,
22(3):293-301.
24. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J:
Expression of Toll-like receptor 9 and response to bacterial CpG
oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol
2005, 141(2):298-306.
25. Sanchez-Munoz F, Fonseca-Camarillo GC, Villeda-Ramirez MA, Barreto-
Zuniga R, Bojalil R, Dominguez-Lopez A, Uribe M, Yamamoto-Furusho JK:
TLR9 mRNA expression is upregulated in patients with active ulcerative
colitis. Inflamm Bowel Dis 2010, 16(8):1267-1268.
26. Burgener IA, Konig A, Allenspach K, Sauter SN, Boisclair J, Doherr MG,
Jungi TW: Upregulation of toll-like receptors in chronic enteropathies in
dogs. J Vet Intern Med 2008, 22(3):553-560.
27. Ewaschuk JB, Backer JL, Churchill TA, Obermeier F, Krause DO, Madsen KL:
Surface expression of Toll-like receptor 9 is upregulated on intestinal
epithelial cells in response to pathogenic bacterial DNA. Infect Immun
2007, 75(5):2572-2579.
28. Lee J, Mo JH, Katakura K, Alkalay I, Rucker AN, Liu YT, Lee HK, Shen C,
Cojocaru G, Shenouda S, et al: Maintenance of colonic homeostasis by
distinctive apical TLR9 signalling in intestinal epithelial cells. Nat Cell Biol
2006, 8(12):1327-1336.
29. Akhtar M, Watson JL, Nazli A, McKay DM: Bacterial DNA evokes epithelial
IL-8 production by a MAPK-dependent, NF-kappaB-independent
pathway. FASEB J 2003, 17(10):1319-1321.
30. Hall JA, Bouladoux N, Sun CM, Wohlfert EA, Blank RB, Zhu Q, Grigg ME,
Berzofsky JA, Belkaid Y: Commensal DNA limits regulatory T cell
conversion and is a natural adjuvant of intestinal immune responses.
Immunity 2008, 29(4):637-649.
31. Fuse K, Katakura K, Sakamoto N, Ohira H: Toll-like receptor 9 gene
mutations and polymorphisms in Japanese ulcerative colitis patients.
World J Gastroenterol 2010, 16(46):5815-5821.
32. Lange NE, Zhou X, Lasky-Su J, Himes BE, Lazarus R, Soto-Quiros M, Avila L,
Celedon JC, Hawrylowicz CM, Raby BA, et al: Comprehensive genetic
assessment of a functional TLR9 promoter polymorphism: no replicable
association with asthma or asthma-related phenotypes. BMC Med Genet
2011, 12:26.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-230X/11/138/prepub
doi:10.1186/1471-230X-11-138
Cite this article as: Sánchez-Muñoz et al.: Transcript levels of Toll-Like
receptors 5, 8 and 9 correlate with inflammatory activity in Ulcerative
Colitis. BMC Gastroenterology 2011 11:138.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Sánchez-Muñoz et al. BMC Gastroenterology 2011, 11:138
http://www.biomedcentral.com/1471-230X/11/138
Page 9 of 9